About this trial
This is a pragmatic, international, multi-centre, phase III open-label randomised controlled trial using an efficient, adaptive, multi-arm, multi-stage (MAMS) design. Patients will be randomised to the Control Arm (Concomitant cisplatin chemotherapy plus radiotherapy) or the Treatment Arm (Induction durvalumab plus control arm and then adjuvant durvalumab)
Patient Profile
Patients with intermediate and high-risk oropharyngeal cancer
Where’s this trial being run?
St James’s Hospital, St Luke’s Radiation Oncology Network @ St James’s Hospital, St Luke’s Radiation Oncology Network @ St Luke’s Hospital, and University Hospital Galway
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | CompARE |
|---|---|
| Number: | 17-14 |
| Full Title: | CompARE – Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer |
| Principal Investigator: | Dr Sinead Brennan |
|---|---|
| Type: | Collaborative |
| Sponsor: | University of Birmingham |
| Recruitment Started: |
Global: July 2015 Ireland: July 2022 |
| Global Recruitment Target: | 785 |
|---|---|
| Ireland Recruitment Target: | 12 |